KYNAMRO
LOE Approachingmipomersen sodium
NDASUBCUTANEOUSSOLUTION
Approved
Jan 2013
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYNAMRO (mipomersen sodium) is an antisense oligonucleotide that reduces apolipoprotein B (apoB) production in patients with severe familial hypercholesterolemia. Administered via subcutaneous injection, it targets the genetic basis of elevated LDL cholesterol in a highly specialized patient population. The drug represents a precision medicine approach to rare, difficult-to-treat dyslipidemia.
LOE Approaching7mo to LOE
With loss-of-exclusivity approaching in 2027 and minimal competitive pressure currently (25%), the commercial team is likely small and focused on defending market share in a niche indication rather than scaling.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.